Selected ongoing clinical trials. (*) (Featured Cme Topic: Female Patient).CERVICAL CANCER * TRETINOIN tretinoin /tret·i·noin/ (tret´i-noin?) the all-trans stereoisomer of retinoic acid, used as a topical keratolytic in the treatment of acne vulgaris and disorders of keratinization and administered orally in the treatment of acute IN PREVENTING CANCER OF THE CERVIX IN PATIENTS WITH CERVICAL NEOPLASIA This Phase I, randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. trial will study the effectiveness of tretinoin in preventing cervical neoplasia from developing into cervical cancer. Women aged 14 years and older with histologically proven cervical dysplasia are eligible. Contact: Dean E. Brenner, University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. Comprehensive Cancer Center, Ann Arbor, MI 48109-0752. (734) 647-1417. * PERIPHERAL STEM CELL TRANSPLANTATION peripheral stem cell transplantation Peripheral stem cell support Oncology A method of replacing hematopoietic cells–HCs destroyed by chemotherapy; stem cells in circulating blood are removed before treatment, then readministered treatment to help BM recovery , WHITE BLOOD CELL INFUSIONS, CHEMOTHERAPY, AND RADIATION THERAPY IN TREATING PATIENTS WITH STAGE IV CERVICAL CANCER This Phase II trial will study the effectiveness of donor peripheral stem cell transplantation plus chemotherapy and total-body irradiation followed by donor white blood cell infusion in treating patients who have stage IV cervical cancer that is associated with human papillomavirus. Women aged up to 65 years with histologically proven stage IVA or IVB IVB Investment Bond IVB Independent Verification Body IVB Inner Vascular Bundle cervical carcinoma are eligible. Contact: George Mathioudakis, Fred Hutchinson Cancer Research Center, Seattle, WA 98109. (206) 598-6100. * COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN TREATING PATIENTS WITH STAGE IVB, RECURRENT, OR PERSISTENT CERVICAL CANCER This Phase III, randomized trial will compare the effectiveness of three different chemotherapy regimens in treating patients with stage IVB, recurrent, or persistent cervical cancer. Women aged 18 years and older with histologically proven stage IVB, recurrent, or persistent carcinoma of the cervix are eligible. Contact: Ronald D. Alvarez, University of Alabama The University of Alabama (also known as Alabama, UA or colloquially as 'Bama) is a public coeducational university located in Tuscaloosa, Alabama, USA. Founded in 1831, UA is the flagship campus of the University of Alabama System. Comprehensive Cancer Center, Birmingham, AL 35294. (205) 934-4986. * BRYOSTATIN-1 PLUS CISPLATIN IN TREATING PATIENTS WITH RECURRENT OR ADVANCED CANCER OF THE CERVIX This Phase II, multicenter trial will study the effectiveness of bryostatin-1 plus cisplatin in treating patients who have recurrent or advanced cancer of the cervix. Women aged 18 years and older with histologically confirmed recurrent or advanced carcinoma of the cervix not amenable to surgery or radiotherapy are eligible. Contact: Scott Wadler, Albert Einstein Comprehensive Cancer Center, Bronx, NY 10461. (718) 904-2754. * CAPECITABINE IN TREATING PATIENTS WITH ADVANCED, PERSISTENT, OR RECURRENT CERVICAL CANCER This Phase II, multicenter trial will study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer. Women with histologically confirmed advanced, persistent, or recurrent squamous cell carcinoma squamous cell carcinoma n. A carcinoma that arises from squamous epithelium and is the most common form of skin cancer. Also called cancroid, epidermoid carcinoma. of the cervix are eligible. Contact: James Tate Thigpen, University of Mississippi Medical Center University of Mississippi Medical Center (UMC) is the health sciences campus of the University of Mississippi (Ole Miss). Located in Jackson, Mississippi (USA), it houses the Schools of Medicine, Dentistry, Nursing, Health Related Professions, and Graduate Studies in the Health , Jackson, MI 39216-4505. (601) 984-5590. * GEMCITABINE AND CISPLATIN IN TREATING PATIENTS WITH REFRACTORY OR RECURRENT CANCER OF THE CERVIX This Phase II, multicenter trial will study the effectiveness of combining gemcitabine and cisplatin in treating patients who have refractory or recurrent cancer of the cervix. Women with histologically confirmed refractory or recurrent squamous cell carcinoma of the cervix are eligible. Contact: Ronald D. Alvarez, University of Alabama Comprehensive Cancer Center, Birmingham, AL 35294. (205) 934-4986. * ARSENIC TRIOXIDE IN TREATING PATIENTS WITH STAGE IVB OR RECURRENT CERVICAL CANCER This Phase II trial will study the effectiveness of arsenic trioxide in treating patients who have stage IVB or recurrent cervical cancer. Women aged 17 years and older who have histologically confirmed stage IVB or recurrent cervical carcinoma that is not amenable to standard curative therapies are eligible. Contact: Steven Soignet, Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New , New York, NY 10021. (212) 639- 8984. * MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. AND CT SCANS TO EVALUATE INVASIVE CERVICAL CANCER BEFORE TREATING PATIENTS This diagnostic trial will determine the effectiveness of MRI and CT scans in evaluating invasive cervical cancer before treating patients. Women with histologically confirmed invasive cervical cancer including invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma are eligible. Contact: Hedvig Hricak, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. (212) 639- 7284. * DX-8951F IN TREATING WOMEN WHO HAVE ADVANCED OR RECURRENT CANCER OF THE CERVIX This Phase II trial will study the effectiveness of DX-8951F in treating women who have advanced or recurrent cancer of the cervix. Women aged 18 years and older with histologically confirmed advanced or recurrent squamous cell carcinoma of the cervix not curable by surgery or radiotherapy are eligible. Contact: Alan N. Gordon, Texas Oncology PA at Baylor-Sammons, Dallas, TX 75246. (214) 370- 1300. OVARIAN CANCER * SQUALAMINE LACTATE Lactate A salt or ester of lactic acid (CH3CHOHCOOH). In lactates, the acidic hydrogen of the carboxyl group has been replaced by a metal or an organic radical. Lactates are optically active, with a chiral center at carbon 2. PLUS CARBOPLATIN IN TREATING PATIENTS WITH RECURRENT OR REFRACTORY STAGE III OR STAGE IV OVARIAN CANCER This Phase II trial will study the effectiveness of combining squalamine lactate and carboplatin in treating patients who have recurrent or refractory stage III or stage IV ovarian cancer. Women aged 18 years and older with histologically confirmed stage III or TV ovarian cancer are eligible. Contact: John A. Glaspy, Jonsson Comprehensive Cancer Center, UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX , Los Angeles, CA 90095-1781. * BICALUTAMIDE AND GOSERELIN goserelin /go·se·rel·in/ (go´se-rel?in) a synthetic gonadotropin-releasing hormone; on prolonged administration it suppresses release of gonadotropins and is used as the acetate salt to treat breast and prostate carcinomas and IN TREATING PATIENTS WITH CANCER OF THE OVARY, FALLOPIAN TUBE, OR PERITONEUM peritoneum (pĕrətənē`əm), multilayered membrane which lines the abdominal cavity, and supports and covers the organs within it. The part of the membrane that lines the abdominal cavity is called the parietal peritoneum. This Phase II trial will study the efficacy of goserelin plus bicalutamide in treating patients who have refractory or recurrent cancer of the ovary, fallopian tube, or peritoneum. Women aged 18 years and older with histologically confirmed epithelial carcinoma arising in the ovary, fallopian tube, or peritoneum, in second or greater remission are eligible. Contact: David R. Spriggs, Memorial SloanKettering Cancer Center, New York, NY 10021. (212) 639-2203. * MONOCLONAL ANTIBODY THERAPY Monoclonal antibody therapy is the use of monoclonal antibodies (or Mab) to specifically target cells. The main objective is stimulating the patient's immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors. IN TREATING PATIENTS SCHEDULED FOR SURGERY TO REMOVE OVARIAN CANCER This Phase I trial will study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian cancer. Women aged 18 years and older with histologically confirmed ovarian carcinoma are eligible. Contact: Chaitanya R. Divgi, Memorial SloanKettering Cancer Center, New York, NY 10021. (212) 639-2459. * COMBINATION CHEMOTHERAPY AND PERIPHERAL STEM CELL TRANSPLANTATION IN TREATING PATIENTS WITH STAGE III OVARIAN CANCER This Phase II trial will study the effectiveness of combination chemotherapy and peripheral stem cell transplantation in treating patients who have undergone surgery for stage III ovarian cancer. Women aged 18 years and older with histologically proven optimally debulked stage III ovarian carcinoma are eligible. Contact: Michael A. Bookman, Fox Chase Cancer Center The Fox Chase Cancer Center is a medical research facility and hospital located in the northeast section of Philadelphia, Pennsylvania, United States. The Center is an independent, non-profit institution which specializes in the treatment and prevention of cancer. , Philadelphia, PA 19111. (215) 728-2987. * VACCINE THERAPY IN TREATING PATIENTS WITH STAGE III, STAGE IV, OR RECURRENT OVARIAN CANCER This Phase I trial will study the efficacy of vaccine therapy in treating patients who have stage III, stage IV, or recurrent ovarian cancer. Women aged 18 years and older who have histologically proven adenocarcinoma of the ovary are eligible. Contact: Samir N. Hkleif, National Cancer Institute, Medicine Branch, Bethesda, AID 20892. (301) 496-0901. * COMBINATION CHEMOTHERAPY IN TREATING PATIENTS WITH OVARIAN CANCER This Phase II trial will study the effectiveness of combination chemotherapy consisting of cisplatin, cyclophosphamide cyclophosphamide /cy·clo·phos·pha·mide/ (-fos´fah-mid) a cytotoxic alkylating agent of the nitrogen mustard group; used as an antineoplastic, as an immunosuppressant to prevent transplant rejection, and to treat some diseases , and paclitaxel plus filgrastim in treating patients with newlydiagnosed and resected stage III ovarian cancer or stage IV ovarian epithelial cancer. Women aged 18 years and older with histologically proven, newly diagnosed, ovarian epithelial cancer are eligible. Contact: Elise C. Kohn, National Cancer Institute, Medicine Branch, Bethesda, MD 20892. (301) 402-2726. * THALIDOMIDE thalidomide (thəlĭd`əmĭd'), sleep-inducing drug found to produce skeletal defects in developing fetuses. The drug was marketed in Europe, especially in West Germany and Britain, from 1957 to 1961, and was thought to be so safe that IN TREATING PATIENTS WITH REFRACTORY OR RESISTANT EPITHELIAL OVARIAN CANCER This Phase II trial will study the effectiveness of thalidomide in treating women who have epithelial ovarian cancer that has not responded to previous therapy. Women with histologically confirmed ovarian epithelial carcinoma are eligible. Contact: Adil Daud, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. (212) 639-6902. * COMBINATION CHEMOTHERAPY PLUS IM-862 IN TREATING PATIENTS WITH RESECTED STAGE III OVARIAN CANCER OR PRIMARY PERITONEAL CANCER Primary peritoneal cancer is a cancer of the cells lining the peritoneum, or abdominal cavity. Prognosis and treatment is the same as for the most common variation of ovarian cancer, epithelial ovarian cancer. This Phase II, randomized trial will study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer. Women aged 18 years and older who have histologically confirmed stage III ovarian epithelial cancer are eligible. Contact: Linda Van Le, Lineberger Comprehensive Cancer Center, UNC (Universal Naming Convention) A standard for identifying servers, printers and other resources in a network, which originated in the Unix community. A UNC path uses double slashes or backslashes to precede the name of the computer. , Chapel Hill, NC 27599-7295. (919) 966-5996. HERPES SIMPLEX * A STUDY ON THE USE OF VALACYCLOVIR TO TREAT HERPES SIMPLEX ENCEPHALITIS This Phase III, double-blind, randomized study will determine if giving valacyclovir to patients with herpes simplex encephalitis can increase the survival rates of these patients and reduce brain and nervous system damage. Both men and women aged 12 years and older with herpes simplex encephalitis are eligible. Contact: National Institute of Allergy and Infectious Diseases, Clinical Virology, 1600 7th Ave S, Suite 616, Birmingham, AL 35294. (205) 934-5316. * A PLACEBO-CONTROLLED PHASE III EVALUATION OF SUPPRESSIVE sup·pres·sive adj. Tending or serving to suppress. Adj. 1. suppressive - tending to suppress; "the government used suppressive measures to control the protest" THERAPY WITH ORAL ACYCLOVIR acyclovir /acy·clo·vir/ (a-si´klo-ver) a synthetic purine nucleoside with selective activity against herpes simplex virus; used as the base or the sodium salt in the treatment of genital and mucocutaneous herpesvirus infections. SUSPENSION FOLLOWING NEONATAL HERPES SIMPLEX VIRUS (HSV (Hue Saturation Value) A color space similar to HSB. See HSB. HSV - hue, saturation, value ) INFECTIONS INVOLVING THE CENTRAL NERVOUS SYSTEM This Phase III, double-blind, placebo-controlled trial will determine whether long-term treatment with oral acyclovir improves the outcome for infants with HSV infection of the brain or spinal cord. Infants aged up to 28 days with an initial diagnosis of central nervous system disease are eligible. Contact: National Institute of Allergy and Infectious Diseases, Clinical Virology, 1600 7th Ave 5, Suite 616, Birmingham, AL 35294. (205) 934-5316. * POLYMORPHISM OF THE HERPES SIMPLEX VIRUS Herpes simplex virus A virus that can cause fever and blistering on the skin, mucous membranes, or genitalia. Mentioned in: Conjunctivitis herpes simplex virus RECEPTOR This natural history study will identify polymorphisms in the sequence of herpes virus entry mediator and determine whether these polymorphisms correlate with susceptibility to infection by herpes simplex virus. Both men and women aged 18 years and older who are known or likely to be seronegative seronegative /se·ro·neg·a·tive/ (-neg´ah-tiv) showing negative results on serological examination; showing a lack of antibody. se·ro·neg·a·tive adj. for HSV-2 are eligible. Contact: National Institute of Allergy and Infectious Diseases (NIA ID), 9000 Rockville Pike, Bethesda, MD 20892. (800) 411-1222. E-mail: prpl@mail.cc.nih.gov. * Prepared by Elaine McClellan-Holm. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion